Sunshine Biopharma Past Earnings Performance
Past criteria checks 0/6
Sunshine Biopharma's earnings have been declining at an average annual rate of -25.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 81.4% per year.
Key information
-25.7%
Earnings growth rate
98.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 81.4% |
| Return on equity | -16.9% |
| Net Margin | -12.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues
Mar 14
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues
Jan 29Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch
Sep 12Sunshine Biopharma acquires Nora Pharma for C$30M
Oct 20We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth
Aug 08Sunshine Biopharma reports 1H results
Aug 04Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs
Apr 17Revenue & Expenses Breakdown
How Sunshine Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 33 | -4 | 13 | 2 |
| 30 Jun 24 | 30 | -4 | 12 | 2 |
| 31 Mar 24 | 27 | -4 | 11 | 2 |
| 31 Dec 23 | 24 | -5 | 11 | 2 |
| 30 Sep 23 | 20 | -27 | 14 | 1 |
| 30 Jun 23 | 15 | -28 | 13 | 1 |
| 31 Mar 23 | 9 | -27 | 12 | 1 |
| 31 Dec 22 | 4 | -27 | 9 | 1 |
| 30 Sep 22 | 0 | -3 | 3 | 1 |
| 30 Jun 22 | 0 | -5 | 2 | 1 |
| 31 Mar 22 | 0 | -7 | 2 | 1 |
| 31 Dec 21 | 0 | -12 | 2 | 1 |
| 30 Sep 21 | 0 | -14 | 2 | 1 |
| 30 Jun 21 | 0 | -11 | 2 | 0 |
| 31 Mar 21 | 0 | -9 | 2 | 0 |
| 31 Dec 20 | 0 | -3 | 1 | 0 |
| 30 Sep 20 | 0 | -2 | 1 | 0 |
| 30 Jun 20 | 0 | -2 | 1 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 0 | -1 | 0 | 0 |
| 30 Jun 19 | 0 | -2 | 1 | 0 |
| 31 Mar 19 | 0 | -2 | 1 | 0 |
| 31 Dec 18 | 0 | -2 | 1 | 0 |
| 30 Sep 18 | 0 | -2 | 1 | 0 |
| 30 Jun 18 | 0 | -1 | 1 | 0 |
| 31 Mar 18 | 0 | -1 | 1 | 0 |
| 31 Dec 17 | 0 | -1 | 1 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 0 |
| 30 Jun 17 | 0 | -3 | 1 | 0 |
| 31 Mar 17 | 0 | -3 | 1 | 0 |
| 31 Dec 16 | 0 | -3 | 1 | 0 |
| 30 Sep 16 | 0 | -3 | 1 | 0 |
| 30 Jun 16 | 0 | -2 | 1 | 0 |
| 31 Mar 16 | 0 | -2 | 0 | 0 |
| 31 Dec 15 | 0 | -2 | 0 | 0 |
| 30 Sep 15 | 0 | -1 | 1 | 0 |
| 30 Jun 15 | 0 | -1 | 1 | 0 |
| 31 Mar 15 | 0 | -2 | 1 | 0 |
| 31 Dec 14 | 0 | -2 | 1 | 0 |
| 30 Sep 14 | 0 | -2 | 1 | 0 |
| 30 Jun 14 | 0 | -2 | 1 | 0 |
| 31 Mar 14 | 0 | -2 | 1 | 0 |
Quality Earnings: SBFM is currently unprofitable.
Growing Profit Margin: SBFM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SBFM is unprofitable, and losses have increased over the past 5 years at a rate of 25.7% per year.
Accelerating Growth: Unable to compare SBFM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SBFM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: SBFM has a negative Return on Equity (-16.88%), as it is currently unprofitable.